Where does Clarus Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Clarus Therapeutics, Inc. ranks #34,767 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Clarus Therapeutics, Inc. hold?

Clarus Therapeutics, Inc. holds 7 US utility patents granted between 2019 and 2022, spanning 3 technology areas.

What is Clarus Therapeutics, Inc.'s Innovation Score?

Clarus Therapeutics, Inc. has an Innovation Score of 23.1 out of 100 (11th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Clarus Therapeutics, Inc. focus on?

Clarus Therapeutics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 7 patents, ranking #2,588 of 6,058 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

Is Clarus Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Clarus Therapeutics, Inc.'s recent grant velocity is +500% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Clarus Therapeutics, Inc.'s patents?

Clarus Therapeutics, Inc.'s patents average 11.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Clarus Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Clarus Therapeutics, Inc.

USPTO PatentsView assignee record - 7 granted patents across 3 technology areas, recorded in grant years 2019–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Clarus ranks #34,767 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 3 technology areas.

#34,767
of 49,997 US assignees by volume: 11th percentile
by Innovation Score (23.1/100): 11.9
avg claims per patent: +500%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R34767 · US Corporation #34,767 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 7 grants
MID-PACK #34,767/49,997
PHOTO-FINISH Citigroup Global…
CPC-NARROW A61P · 3 areas
INNOV-THIN 23.1/100
CLAIMS-PAR 11.9 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +500% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Citigroup Global Markets Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Clarus’s 23.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (31%) Velocity 2.7 pts (12%) Breadth 6.1 pts (26%) Claim depth 7.1 pts (31%)

Qualcomm Incorporated · highest

85
Clarus Therapeutics · this assignee

23
3D Lighting… · lowest

7

What this shows Clarus's Innovation Score is 23.1/100 (11th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Clarus?

Each dot is one of Clarus’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Clarus’s own 11.9 claims/patent is at or below the 17.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Clarus vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Clarus's grants concentrate

Clarus Therapeutics, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2019. By volume, Clarus sits between Citigroup Global Markets Inc. and Clean-Shot Archery, Inc..

Clarus's three-year grant acceleration

Clarus Therapeutics, Inc. shows 2 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Citigroup Global…

7
City Universsity…

7
Clantech

7
Clarity Pharmaceu…

7
Clean Air-enginee…

7
Clean Diesel (Cdt…

7
Clean Train Propu…

7
Clean-shot Archery

7
Clarus Therapeuti… ◀

7

What this shows Clarus holds 7 patents at rank #34,832, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Clarus

By rank, the assignees closest to #34,832 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Clarus's primary technology class.

Clarus's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

23 11th percentile higher than 11% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Clarus Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	1	14.3%
2020	2	28.6%
2021	2	28.6%
2022	2	28.6%

Which technologies does Clarus Therapeutics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 7

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 7

C07J - Steroids 2

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Clarus Therapeutics, Inc.'s patent record in context - here's where to go next.

Clarus Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #34,767 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Clarus Therapeutics, Inc. against Citigroup Global Markets Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 23.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.